ARINA-1 (RVN-301)
Non-Cystic Fibrosis Bronchiectasis (NCFBE)
Key Facts
About Renovion
Renovion is a private, clinical-stage biotech developing ARINA-1, a novel nebulized therapy targeting the vicious cycle of mucus, inflammation, and infection in chronic lung diseases. The company has generated positive Phase 2 top-line results in NCFBE and is actively enrolling a trial in lung transplant, positioning it in underserved markets with significant unmet need. Led by a seasoned team with deep respiratory expertise, Renovion's approach aims to improve mucociliary clearance and quality of life for patients with limited treatment options.
View full company profileAbout Renovion
Renovion is a private, clinical-stage biotech developing ARINA-1, a novel nebulized therapy targeting the vicious cycle of mucus, inflammation, and infection in chronic lung diseases. The company has generated positive Phase 2 top-line results in NCFBE and is actively enrolling a trial in lung transplant, positioning it in underserved markets with significant unmet need. Led by a seasoned team with deep respiratory expertise, Renovion's approach aims to improve mucociliary clearance and quality of life for patients with limited treatment options.
View full company profileAbout Renovion
Renovion is a private, clinical-stage biotech developing ARINA-1, a novel nebulized therapy targeting the vicious cycle of mucus, inflammation, and infection in chronic lung diseases. The company has generated positive Phase 2 top-line results in NCFBE and is actively enrolling a trial in lung transplant, positioning it in underserved markets with significant unmet need. Led by a seasoned team with deep respiratory expertise, Renovion's approach aims to improve mucociliary clearance and quality of life for patients with limited treatment options.
View full company profileTherapeutic Areas
Other Non-Cystic Fibrosis Bronchiectasis (NCFBE) Drugs
| Drug | Company | Phase |
|---|---|---|
| LBP for NCFBE | Alveolus Bio | Preclinical |